Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals is a U.S.-based biopharmaceutical company focused on endocrine diseases and endocrine-related tumors. It develops small-molecule therapies that target GPCR biology, with PALSONIFY (paltusotine) as its first approved product and a broader pipeline spanning acromegaly, Cushing syndrome, congenital adrenal hyperplasia, neuroendocrine tumors and other endocrine disorders.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved and marketed therapy for acromegaly, anchored by PALSONIFY.
Programs in Phase 2/3 and other advanced development stages, including paltusotine and atumelnant.
SST2-targeted and oncology-adjacent programs such as CRN09682 and related discovery assets.
Earlier research programs across endocrine and metabolic diseases.
Products
Reported · share of revenue- Products70.4 %
- License and Service29.6 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Crinetics sells primarily to specialty physicians and healthcare systems treating rare endocrine disorders, with initial commercialization centered on the U.S. market. Its future customer base also includes international partners and patients reached through licensing arrangements, such as Japan via Sanwa Kagaku Kenkyusho. Because the company’s products address uncommon diseases, access depends heavily on specialist diagnosis, payer coverage and reimbursement decisions.
Endocrinologists and rare-disease specialists prescribing PALSONIFY and future endocrine therapies.
Commercial and government payers that influence access, formulary placement and patient uptake.
Partners such as Sanwa in Japan that develop and commercialize paltusotine locally.
Adults with acromegaly and other endocrine disorders who benefit from chronic oral therapy.
Collaborators and future partners for SST2-expressing tumors and radiopharmaceutical programs.
Strategy
Crinetics is transitioning from a development-stage biotech into a commercial rare-disease company while continuing to advance a broad endocrine pipeline. Near term, the focus is on launching PALSONIFY, expanding access and reimbursement, and progressing paltusotine and atumelnant through late-stage development. Longer term, the company aims to build a multi-product franchise in endocrine disease and selectively use partnerships to extend reach outside the U.S.
The approved product is the first source of product revenue and validates the platform.
Additional indications and geographies can extend the product lifecycle and broaden the addressable market.
A diversified pipeline reduces dependence on a single product and supports long-term growth.
Geography
Crinetics is headquartered in the United States and currently commercializes PALSONIFY in the U.S. through a specialty sales and distribution model. It is also pursuing international expansion, including regulatory review in Europe and a licensed commercialization pathway in Japan. Manufacturing is globally distributed, with drug substance synthesized in India, an optimization step in Portugal, and finished drug product tableted in the U.S.
Risks
Crinetics remains exposed to the execution risk of a newly commercialized rare-disease product, including physician adoption, payer access and supply-chain reliability. Its pipeline also depends on successful clinical development and regulatory review, while the company continues to burn cash and may need additional capital over time. As a global developer, it also faces IP, manufacturing, foreign exchange and cross-border regulatory risks typical of biopharma companies.
- Limited commercialization track recordImpact: HighLikelihood: Medium
The company has FDA approval but has not yet proven sustained commercial execution for PALSONIFY.
Exposure: U.S. launch and specialty market uptake
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company does not own commercial manufacturing facilities and relies on CMOs and suppliers.
Exposure - Clinical development failureImpact: HighLikelihood: Low
Pipeline value depends on positive trial outcomes and regulatory approvals across multiple indications.
Exposure - Capital requirements and dilutionImpact: MediumLikelihood: High
Ongoing R&D, launch costs and clinical programs can outpace internally generated cash flow.
Exposure: Future financings if product revenue ramps slowly
- Foreign regulatory and reimbursement exposureImpact: MediumLikelihood: Low
International expansion depends on approvals, pricing and reimbursement decisions outside the U.S.
Exposure: Europe and Japan
Accounting
Judgemental itemsRevenue has historically come from grants and license agreements, so timing depends on performance obligations and milestones.
Impact: Can create uneven quarterly revenue and deferred revenue balances
PALSONIFY commercialization is new, so channel, returns and distributor accounting may become important.
Impact: May affect reported sales timing and gross-to-net deductions
Clinical and preclinical work is outsourced, requiring judgment in estimating unpaid trial and vendor costs.
Impact: Affects operating expense and period-to-period comparability
A significant noncash expense for a growth-stage biotech with heavy hiring and retention needs.
Impact: Can materially widen reported net losses
Management explicitly cites leases and accrued expenses as key estimates in financial reporting.
Impact: Affects liabilities and operating cost presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Neurocrine Biosciences, Inc
NBIX · Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a U.S.-based biopharmaceutical company focused on neuroscience and related endocrine disorders.
Palatin Technologies, Inc
PTN · Pharmaceutical Preparations
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Prenetics Global Ltd
PRE · Pharmaceutical Preparations
Prenetics Global Ltd is a U.S.-listed health sciences company focused on consumer health, wellness, and longevity products through its IM8 brand and the CircleDNA testing business.
Edgewise Therapeutics, Inc.
EWTX · Pharmaceutical Preparations
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Last updated: 24/09/2026